HM 15136

Drug Profile

HM 15136

Alternative Names: LAPSGlucagon Analog; HM15136

Latest Information Update: 05 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Hanmi Pharmaceutical
  • Class Antihypoglycaemics; Pancreatic hormones
  • Mechanism of Action Glucagon receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Hyperinsulinaemia

Most Recent Events

  • 25 Apr 2017 Hanmi Pharmaceutical announces intention to submit IND application in between fourth quarter of 2017 to second quarter of 2018 for initiation of a phase I trial in Hyperinsulinaemia (Hanmi Pharmaceuticals pipeline, April 2017)
  • 25 Apr 2017 Preclinical trials in Hyperinsulinaemia in South Korea (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top